0/553854

is Deing deposited with the U.S. Postal C20 Rec't PCT/PTO 19 OCT 2003 I hereby certify that this correspondence Service as Express Mail, Airbill No. EV 711312153 US, in an envelope adules to: Mail Stop PCT, Commissioner for Ratents P. D. Box 1,50 Alexandria, VA

22313-1450, on the date shown beld Dated: October 19, 2005

(Peter C. Lauro)

Docket No.: 59756DIV2(49949)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Milan R. Uskokovic, et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For:

USE OF GEMINI VITAMIN D3 COMPOUNDS FOR TREATING

HYPERTENSION (as amended)

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicants hereby direct the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith, which is a U.S. national phase of international application no. PCT/US2004/013703, filed April 30, 2004. The references listed on the attached PTO/SB/08 were cited in the International Search Report issued in the aforementioned PCT international application. A copy of the International Search Report is enclosed.

Applicants have not provided copies of the references inasmuch as these have already been provided to the United States Receiving Office.

Application No.: Not Yet Assigned

Docket No.: 59756DIV2(49949)

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Pursuant to 37 C.F.R. 1.97(b)(2), Applicants submit that no fees are required for consideration and entry of this Information Disclosure Statement. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 04-1105, under Order No. 59756DIV1. A duplicate copy of this paper is enclosed.

Applicants submit that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and respectfully request the Examiner to consider the listed references.

Respectfully submitted,

EDWARDS & ANGELL, LLP

Peter C. Lauro, Ésq. Registration No.: 32,360 Attorney for Applicants

P.O. Box 55874 Boston, Massachusetts 02205 617-517-5509

Dated: October 19, 2005

JC20 Rec'd PCT/PTO 19 OCT 2009

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	Mariga do de la companya della companya della companya de la companya de la companya della compa	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	Concurrently Herewith	
				First Named Inventor	Milan R. Uskokovic	
				Art Unit	N/A	
				Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	59756DIV2(49949)	

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 6,030,962 A	02/29/00	MANCHAND et al	
		US 6,008,209 A	12/28/99	MANCHAND et al	

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		WO 98/49138 A2	11/05/98	F. HOFFMAN-LA ROCHE AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	
Sidnature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.